🆕 publication | EPI-PHARE co-signe un article dans la revue Pharmacoepidemiology & Drug Safety

💡 Potentially inappropriate medications in nursing homes and the community older adults using the French health insurance databases

👉 https://doi.org/10.1002/pds.5575

#EpiVerse #PharmacoEpidemiolgy

🆕 publication | EPI-PHARE co-signe un article dans la revue Vaccines

💡Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study.

➡️ Étude nationale sur 6,8 millions d’enfants, menée en collaboration avec l'Inserm et l'AP-HP.

➡️ Les vaccins ROR (rougeole, oreillons et rubéole) ne protègent pas contre le Covid sévère chez les enfants.
#EpiVerse #PharmacoEpidemiolgy

👉https://doi.org/10.3390/vaccines10111938

🆕publication | EPI-PHARE signe un article dans Scientific Reports

💡TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System

#EpiVerse #PharmacoEpidemiolgy

👉 https://www.nature.com/articles/s41598-022-24050-7

💡 Created by ANSM (French health Authority) and CNAM (French Health Insurance), EPI-PHARE carries out, pilots and coordinates pharmaco-epidemiological studies using complex and massive data from the French National Health Data System to enlighten public authorities in their decision-making.

💡 EPI-PHARE aims to produce new knowledge on the use, misuse, benefits and risks of medicines and health products in real life.

👉 https://www.epi-phare.fr/en/who-are-we/

#EpiVerse #RealWorldData #PharmacoEpidemiolgy